I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | | 1 HKD | | 1,000,000,000 | 本月底法定/註冊股本總額： HKD 1,000,000,000 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集 ...

Group 1 - The company, China Life Group (08296.HK), reported a revenue of RMB 36.039 million for the six months ending June 30, 2025, representing a year-on-year increase of 5% [1] - The gross profit for the same period was RMB 13.212 million, which is a year-on-year increase of 10.4% [1] - The loss attributable to the company's owners was RMB 4.803 million, an improvement from a loss of RMB 8.665 million in the same period last year [1] - The basic loss per share was RMB 0.51 [1]

Group 1 - The company reported a revenue of RMB 36.039 million for the six months ending June 30, 2025, representing a year-on-year increase of 4.82% [1] - The loss attributable to shareholders narrowed to RMB 4.803 million, a decrease of 44.57% compared to the previous year [1] - The basic loss per share was recorded at 0.51 cents [1]

Group 1 - The company reported a revenue of RMB 36.039 million for the six months ending June 30, 2025, representing a year-on-year increase of 4.82% [1] - The loss attributable to shareholders narrowed to RMB 4.803 million, a decrease of 44.57% compared to the previous year [1] - The basic loss per share was recorded at 0.51 cents [1]

[Company Information and GEM Characteristics](index=1&type=section&id=%E5%85%AC%E5%8F%B8%E4%BF%A1%E6%81%AF%E4%B8%8EGEM%E7%89%B9%E8%89%B2) [Company Overview](index=10&type=section&id=%E5%85%AC%E5%8F%B8%E6%A6%82%E5%86%B5) China Life Group Limited (the Company) is incorporated in the Cayman Islands, with shares listed on the Stock Exchange's GEM, primarily engaging in investment holding with diversified subsidiary businesses across funeral services, cemetery sales, and biotechnology instrument sales - The Company is incorporated in the Cayman Islands, with shares listed on the Stock Exchange's GEM, primarily engaged in **investment holding**[12](index=12&type=chunk) - The Group's subsidiaries have diversified businesses, including funeral services in China, Taiwan, and Hong Kong, cemetery plot sales and maintenance in Vietnam, and sales of biotechnology instruments and electronic products in Hong Kong[12](index=12&type=chunk) [GEM Listing Characteristics and Risk Disclosure](index=1&type=section&id=GEM%E4%B8%8A%E5%B8%82%E7%89%B9%E7%82%B9%E4%B8%8E%E9%A3%8E%E9%99%A9%E6%8F%90%E7%A4%BA) The Stock Exchange's GEM market provides a listing platform for SMEs, typically involving higher investment risks and potential market volatility, with no guarantee of high liquidity - The GEM market is positioned to provide a listing platform for small and medium-sized companies, with relatively **higher investment risks**[2](index=2&type=chunk)[5](index=5&type=chunk) - GEM securities may be subject to significant market volatility risks and do not guarantee **high liquidity**[2](index=2&type=chunk)[5](index=5&type=chunk) [Condensed Consolidated Financial Statements](index=4&type=section&id=%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8) [Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income](index=4&type=section&id=%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E6%8D%9F%E7%9B%8A%E5%8F%8A%E5%85%B6%E4%BB%96%E5%85%A8%E9%9D%A2%E6%94%B6%E7%9B%8A%E8%A1%A8) For the six months ended June 30, 2025, Group revenue increased to RMB 36,039 thousand, gross profit grew by 10.4% to RMB 13,212 thousand, and the loss for the period narrowed to RMB 7,172 thousand despite an operating loss of RMB 5,182 thousand Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income (For the six months ended June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Revenue | 36,039 | 34,383 | +4.8% | | Cost of sales and services | (22,827) | (22,412) | +1.9% | | Gross profit | 13,212 | 11,971 | +10.4% | | Operating loss | (5,182) | (6,745) | -23.2% | | Loss before tax | (5,931) | (7,673) | -22.7% | | Loss for the period | (7,172) | (8,909) | -19.5% | | Loss attributable to owners of the Company | (4,803) | (8,665) | -44.6% | | Basic loss per share (RMB cents) | (0.51) | (0.96) | -46.8% | | Diluted loss per share (RMB cents) | (0.38) | (1.00) | -62.0% | [Condensed Consolidated Statement of Financial Position](index=6&type=section&id=%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E8%B4%A2%E5%8A%A1%E7%8A%B6%E5%86%B5%E8%A1%A8) As of June 30, 2025, the Group's non-current assets slightly increased to RMB 54,750 thousand, current assets marginally decreased to RMB 195,914 thousand, and current liabilities rose to RMB 138,888 thousand, resulting in a decrease in net current assets and total equity to RMB 99,456 thousand Condensed Consolidated Statement of Financial Position (As of June 30) | Indicator | 2025年6月30日 (RMB'000) | 2024年12月31日 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Non-current assets | 54,750 | 54,248 | +0.9% | | Current assets | 195,914 | 196,378 | -0.2% | | Current liabilities | 138,888 | 133,611 | +3.9% | | Net current assets | 57,026 | 62,767 | -9.1% | | Total assets less current liabilities | 111,776 | 117,015 | -4.5% | | Non-current liabilities | 12,320 | 13,481 | -8.6% | | Net assets | 99,456 | 103,534 | -3.9% | | Total equity | 99,456 | 103,534 | -3.9% | [Condensed Consolidated Statement of Changes in Equity](index=8&type=section&id=%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E6%9D%83%E7%9B%8A%E5%8F%98%E5%8A%A8%E8%A1%A8) For the six months ended June 30, 2025, equity attributable to owners of the Company decreased from RMB 123,452 thousand to RMB 119,703 thousand, primarily due to a loss of RMB 4,803 thousand and non-controlling interests' capital injection of RMB 1,481 thousand Condensed Consolidated Statement of Changes in Equity (For the six months ended June 30) | Indicator | 2025年6月30日 (RMB'000) | 2024年12月31日 (RMB'000) | | :--- | :--- | :--- | | Equity attributable to owners of the Company (beginning of period) | 123,452 | 123,718 | | Loss for the period | (4,803) | (8,665) | | Exchange differences on translation of foreign operations | 1,054 | 1,797 | | Capital injection from non-controlling interests | 1,481 | 240 | | Equity attributable to owners of the Company (end of period) | 119,703 | 122,398 | [Condensed Consolidated Statement of Cash Flows](index=9&type=section&id=%E7%AE%80%E6%98%8E%E7%BB%BC%E5%90%88%E7%8E%B0%E9%87%91%E6%B5%81%E9%87%8F%E8%A1%A8) For the six months ended June 30, 2025, net cash used in operating activities significantly decreased to RMB 1,989 thousand, net cash from investing activities was RMB 74 thousand, net cash used in financing activities was RMB 1,255 thousand, and period-end cash and bank balances increased to RMB 110,858 thousand Condensed Consolidated Statement of Cash Flows (For the six months ended June 30) | Indicator | 2025 (RMB'000) | 2024 (RMB'000) | Change (%) | | :--- | :--- | :--- | :--- | | Net cash used in operating activities | (1,989) | (12,145) | -83.6% | | Net cash from investing activities | 74 | 704 | -89.5% | | Net cash (used in)/from financing activities | (1,255) | 1,534 | -181.8% | | Net decrease in cash and cash equivalents | (3,170) | (9,907) | -68.0% | | Cash and cash equivalents as of June 30 | 110,858 | 118,770 | -6.7% | [Notes to the Financial Statements](index=10&type=section&id=%E8%B4%A2%E5%8A%A1%E6%8A%A5%E8%A1%A8%E9%99%84%E6%B3%A8) [General Information](index=10&type=section&id=%E4%B8%80%E8%88%AC%E8%B5%84%E6%96%99) The Group primarily engages in investment holding, with diversified subsidiary businesses including funeral services in China, Taiwan, and Hong Kong, cemetery sales and maintenance in Vietnam, and sales of high-end biotechnology instruments and other

[Supplemental Announcement to 2024 Annual Report](index=1&type=section&id=Supplemental%20Announcement%20to%202024%20Annual%20Report) [Announcement Background](index=1&type=section&id=Announcement%20Background) This announcement supplements the 2024 annual report of China Life Group Limited (Stock Code: 8296) regarding share placement proceeds utilization for the fiscal year ended December 31, 2024 - This announcement supplements the "Share Placement" section of China Life Group Limited's (Stock Code: 8296) 2024 annual report[3](index=3&type=chunk) - The announcement provides additional details on the use of net proceeds for the fiscal year ended December 31, 2024, as per GEM Rule 18.32(8)[5](index=5&type=chunk) [Use of Proceeds from Share Placement](index=1&type=section&id=Use%20of%20Proceeds%20from%20Share%20Placement) This section details the net proceeds from the share placement, their original intended use, and actual utilization for general working capital as of December 31, 2024 [Net Proceeds and Original Intended Use](index=1&type=section&id=Net%20Proceeds%20and%20Original%20Intended%20Use) Net proceeds of approximately **HKD 5.7 million** (RMB 5.347 million) from the share placement were intended for general working capital to ensure liquidity - The share placement generated net proceeds of approximately **HKD 5.7 million** (equivalent to approximately **RMB 5.347 million**)[4](index=4&type=chunk) - These net proceeds were designated to supplement general working capital, ensuring adequate liquidity for the Group's operations in Hong Kong[4](index=4&type=chunk) [Details of Fund Utilization as of December 31, 2024](index=2&type=section&id=Details%20of%20Fund%20Utilization%20as%20of%20December%2031%2C%202024) As of December 31, 2024, all **RMB 5.347 million** net proceeds were fully utilized for general working capital, with no unutilized balance Details of Share Placement Proceeds Utilization for the Year Ended December 31, 2024 | Allocated Use of Proceeds | Percentage | Amount Utilized (RMB '000) | Unutilized Balance (RMB '000) | | :------------------------ | :--------- | :------------------------- | :---------------------------- | | General Working Capital | 100.0% | 5,347 | - | - The Board confirms that this supplementary information does not alter any other data in the 2024 annual report, which remains unchanged[5](index=5&type=chunk) [Board Statements and Confirmation](index=2&type=section&id=Board%20Statements%20and%20Confirmation) The Board confirms the announcement's accuracy, completeness, and compliance with GEM Listing Rules, with no misleading or omitted material information - The Board confirms that all information in this announcement is accurate, complete, not misleading or fraudulent, and omits no material facts[6](index=6&type=chunk) - This announcement is published in compliance with GEM Listing Rules and will be available on the Stock Exchange and company websites for seven days from publication[6](index=6&type=chunk)

香港交易及結算所有限公司及香港聯合交易所有限公司對本公佈的內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公佈全部或任何 部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8296） 董事會會議通告 中國生命集團有限公司（「本公司」）之董事（「董事」）會（「董事會」）謹此宣布，董事 會會議將於二零二五年八月二十七日（星期三）舉行，以便處理下列事項： 承董事會命 中國生命集團有限公司 主席兼執行董事 許建春 香港，二零二五年八月十一日 – 1 – 1) 省覽及通過本公司及其附屬公司截至二零二五年六月三十日止六個月之未經 審核綜合財務報表（「中期業績」）； 2) 通過將中期業績公告稿本及通過中期業績公告刊登於香港聯合交易所有限公 司之網站及本公司網站； 3) 考慮及通過派發中期股息（如有）； 4) 考慮及通過暫停辦理本公司之股東過戶登記手續（如有需要）；及 5) 處理其他事項（如有）。 於本公告日期，董事會由執行董事許建春先生及劉添財先生，和獨立非執行董事 齊忠偉先生、楊菁菁博士及胡朝暉女士組成。 本公 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告之內容概不負責， 對其準確性或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何 部分內容而產生或因倚賴該等內容而引致之任何損失承擔任何責任。 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：8296） 補充公告 董事會認為，將目標集團於二零二四年十二月三十一日之財務狀況與代價比較， 代價似乎較出售集團於二零二四年十二月三十一日之資產淨值有所溢價。然而， 於全面計入外幣換算儲備虧損後，從本集團即將刊發之損益表角度而言，出售事 項實際上於扣除相關開支前已達致收支平衡，錄得100,000港元之收益。鑑於上述， 董事會認為代價屬公平合理，原因為其確保，於完成後，出售事項不會對本公司 的盈利、資產或負債造成任何重大不利影響。 – 1 – 除上文所披露者外，該公告所載所有其他資料維持不變，並就所有目的而言繼續 有效。本公告為該公告之補充，應與該公告一併閱讀。 須予披露交易 出售出售公司的全部股權 茲提述中國生命集團有限公司（「本公司」）日期為二零二五年七月三十日的公告（「該 公告」），內容有關出售出售公司。除另有界定者外，本公告 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年7月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: 中國生命集團有限公司 呈交日期: 2025年8月1日 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 08296 | 說明 | | | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | | 法定/註冊股本 | | | 上月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | | 增加 / 減少 (-) | | | | | | | HKD | | | | 本月底結存 | | | 1,000,000,000 | HKD | | 1 | HKD | | 1,000,000,000 | 本月底法定/註冊股本 ...

Core Viewpoint - China Life Group (08296) has announced the sale of its subsidiary, Junqun Development Limited, for HKD 10 million, aiming to terminate its operations in Vietnam due to minimal revenue generation and unmet business growth expectations [1] Group 1: Sale Agreement - The sale agreement was established between the seller, China Life Group Limited, and the buyer, Hao Shan Limited, with a transaction value of HKD 10 million [1] - The decision to sell was made after careful consideration of the subsidiary's financial performance since its establishment [1] Group 2: Business Strategy - The sale is intended to streamline the company's operations and allow for more effective resource allocation to other business segments with better growth prospects [1] - This move is also aimed at reserving additional resources for future business development opportunities [1]